Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard B Warren

Showing results (101-110 of 257) with videos related to

Pageof 26
Sort By:
The Journal of Investigative Dermatology|November 24, 2007
Polymorphisms in the IL-12beta and IL-23R genes are associated with psoriasis of early onset in a UK cohortRhodri L L Smith, Richard B Warren, Steve Eyre, et al.
Rheumatology and Therapy|April 8, 2026
Correction: Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect ComparisonPhilip J Mease, Richard B Warren, Peter Nash, et al.
JAMA Dermatology|July 6, 2022
Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With PsoriasisZenas Z N Yiu, Gabrielle Becher, Brian Kirby, et al.
Journal of Drugs in Dermatology : JDD|March 9, 2016
Effectiveness of Subcutaneous Methotrexate in Chronic Plaque PsoriasisPaul Devakar Yesudian, Joyce Leman, Periasamy Balasubramaniam, et al.
The British Journal of Dermatology|January 28, 2026
Serious infection risk in people treated with infliximab for severe psoriasisHeber Rew Bright Bright, Catherine H Smith, Philip Laws, et al.
Dermatology and Therapy|October 6, 2023
Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-AnalysisApril W Armstrong, Richard B Warren, Yichen Zhong, et al.
The British Journal of Dermatology|April 4, 2023
Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)Duc Binh Phan, Anthony P Bewley, Catherine H Smith, et al.
The Lancet. Rheumatology|January 22, 2024
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind studyKim Papp, Richard B Warren, Lawrence Green, et al.
Dermatology and Therapy|September 16, 2024
Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with PsoriasisMatthias Augustin, Alice B Gottlieb, Mark Lebwohl, et al.
The British Journal of Dermatology|May 4, 2026
Serious infection risk with systemic treatments for psoriasis: A cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)Heber Rew Bright Bright, Catherine H Smith, Philip Laws, et al.
Pageof 26

Showing results (101-110 of 257) with videos related to

Sort By:
Pageof 26
The Journal of Investigative Dermatology|November 24, 2007
Polymorphisms in the IL-12beta and IL-23R genes are associated with psoriasis of early onset in a UK cohortRhodri L L Smith, Richard B Warren, Steve Eyre, et al.
Rheumatology and Therapy|April 8, 2026
Correction: Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect ComparisonPhilip J Mease, Richard B Warren, Peter Nash, et al.
JAMA Dermatology|July 6, 2022
Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With PsoriasisZenas Z N Yiu, Gabrielle Becher, Brian Kirby, et al.
Journal of Drugs in Dermatology : JDD|March 9, 2016
Effectiveness of Subcutaneous Methotrexate in Chronic Plaque PsoriasisPaul Devakar Yesudian, Joyce Leman, Periasamy Balasubramaniam, et al.
The British Journal of Dermatology|January 28, 2026
Serious infection risk in people treated with infliximab for severe psoriasisHeber Rew Bright Bright, Catherine H Smith, Philip Laws, et al.
Dermatology and Therapy|October 6, 2023
Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-AnalysisApril W Armstrong, Richard B Warren, Yichen Zhong, et al.
The British Journal of Dermatology|April 4, 2023
Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)Duc Binh Phan, Anthony P Bewley, Catherine H Smith, et al.
The Lancet. Rheumatology|January 22, 2024
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind studyKim Papp, Richard B Warren, Lawrence Green, et al.
Dermatology and Therapy|September 16, 2024
Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with PsoriasisMatthias Augustin, Alice B Gottlieb, Mark Lebwohl, et al.
The British Journal of Dermatology|May 4, 2026
Serious infection risk with systemic treatments for psoriasis: A cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)Heber Rew Bright Bright, Catherine H Smith, Philip Laws, et al.
Pageof 26